Genmab — November 2017
-
Janssen Korea’s ‘paradigm-changing’ blood cancer drug gets approval http://www.koreabiomed.com/news/articleView.html?idxno=1878
-
and if you speak chinese; Darzalex entered the Top100 sales worldwide for the first 9months of the year http://www.chinapharm.com.cn/News/Detail.aspx?ID=39600 or via google translate https://translate.google.nl/translate?hl=nl&sl=zh-CN&tl=en&u=http%3A%2F%2Fwww.chinapharm.com.cn%2FNews%2FDetail.aspx%3FID%3D39600
-
Ham Per Hansen skal man vist ikke tage alt for seriøst - 15% fald over 3 måneder på basis af JJ's Q3 rapportering...
-
I øvrigt, så må udlandet udsalg af GEN aktier over den seneste måned have været ret markant, hvis man tager BlackRocks ~2% point forøgelse i betragtning
-
mon ikke snarere der var tale om 20% på en måned?
-
eftersom det event han hentyder til, skete for 1 måned siden
-
men Per Hansen har nu helt ret i, at det er frygtelig ringe rapportering fra GEN's side
-
Rasmus Botoft: "Vi skal længere "ned"... vi skal helt "ned" i sindet... nu er du bange!!... nu-men-sas... nu-men-sas!"
-
Ja, det må du sgu nok sige concillado - usikkerher er gift for aktier.
-
GEN har altid trukket regnskabet til meget sent
-
lidt underligt egentligt, da der ikke kan gå meget energi i at lave en opdateret opgørelse over omsætningen...
-
Johnson & Johnson's Janssen Biotech unit entered a licensing deal with Zymeworks potentially worth more than $1.4 billion to develop up to six bispecific antibodies directed against undisclosed therapeutic targets, Zymeworks announced Monday. Under the agreement, which includes an upfront payment from Janssen of $50 million, the drugmaker will obtain a royalty-bearing license to use Zymeworks' Azymetric and EFECT platforms
-
As part of the transaction, Zymeworks is eligible to receive up to $282 million in development and up to $1.12 billion in commercial milestone payments, and tiered royalties on potential sales. Janssen also has the option to develop two additional bispecific programmes subject to a future option payment.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind